Skip to main content
Top
Published in: Pediatric Nephrology 10/2009

Open Access 01-10-2009 | Educational Feature

Heritable forms of hypertension

Author: V. Matti Vehaskari

Published in: Pediatric Nephrology | Issue 10/2009

Login to get access

Abstract

Among the causes of secondary hypertension are a group of disorders with a Mendelian inheritance pattern. Recent advances in molecular biology have unveiled the pathogenesis of hypertension in many of these conditions. Remarkably, the mechanism in every case has proved to be upregulation of sodium (Na) reabsorption in the distal nephron, with accompanying expansion of extracellular volume. In one group, the mutations involve the Na-transport machinery in distal tubule cells themselves: the distal convoluted tubule (DCT) cell and the principal cell of the collecting duct. Examples include Liddle’s syndrome, with an activating mutation of epithelial Na channel (ENaC); two types of Gordon’s syndrome, with mutations in two regulatory kinases [with no lysine (K) serine/threonine protein kinases (WNK)1 or WNK4]; and apparent mineralocorticoid excess (AME), with an inactivating mutation in the glucocorticoid-metabolizing 11β-hydroxysteroid dehydrogenase type 2 enzyme (11HD2). In another group, abnormal adrenal steroid production leads to inappropriate stimulation of the mineralocorticoid receptor (MR) in the distal nephron. The pathophysiology may involve inappropriate production of aldosterone [in glucocorticoid-remediable aldosteronism (GRA) and familial hyperaldosteronism type II (FH II)], of cortisol (in familial glucocorticoid resistance), or of other steroid metabolites (in congenital adrenal hyperplasia and GRA). In contrast to earlier beliefs, hypertension in many of the inherited disorders may be mild, and electrolyte and acid-base abnormalities are often not present. Monogenic hypertension should therefore enter the differential diagnosis of any child or adolescent with hypertension. Plasma renin activity (PRA) is the appropriate screening tool for all types of inherited hypertension.
Literature
1.
go back to reference Guyton AC, Coleman RG, Cowley AW Jr, Scheel KW, Manning RD Jr, Norman RA Jr (1972) Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52:584–594PubMed Guyton AC, Coleman RG, Cowley AW Jr, Scheel KW, Manning RD Jr, Norman RA Jr (1972) Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52:584–594PubMed
2.
go back to reference Hall JE, Mizelle L, Hildebrandt DA, Brands MW (1990) Abnormal pressure natriuresis. A cause or a consequence of hypertension? Hypertension 15:547–559PubMed Hall JE, Mizelle L, Hildebrandt DA, Brands MW (1990) Abnormal pressure natriuresis. A cause or a consequence of hypertension? Hypertension 15:547–559PubMed
3.
go back to reference Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB, Knepper MA (1998) The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci USA 95:14552–14557PubMed Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB, Knepper MA (1998) The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci USA 95:14552–14557PubMed
4.
go back to reference Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP (2003) Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but no mutant WNK4. Proc Natl Acad Sci 100:680–684PubMed Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP (2003) Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but no mutant WNK4. Proc Natl Acad Sci 100:680–684PubMed
5.
go back to reference Yang CL, Angell J, Mitchell R, Ellison DH (2003) WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 111:1039–1045PubMedPubMedCentral Yang CL, Angell J, Mitchell R, Ellison DH (2003) WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 111:1039–1045PubMedPubMedCentral
6.
go back to reference Xu BE, Stippes S, Chu PY, Lazrak A, Li XJ, Lee BH, English JM, Ortega B, Huang CL, Cobb MH (2005) WNK1 activates SGK1 to regulate the epithelial sodium channel. Proc Natl Acad Sci USA 102:10315–10320PubMed Xu BE, Stippes S, Chu PY, Lazrak A, Li XJ, Lee BH, English JM, Ortega B, Huang CL, Cobb MH (2005) WNK1 activates SGK1 to regulate the epithelial sodium channel. Proc Natl Acad Sci USA 102:10315–10320PubMed
7.
go back to reference Gamba G (2005) Role of WNK kinases in regulating tubular salt and potassium transport and in the development of hypertension. Am J Physiol 288:F245–F252 Gamba G (2005) Role of WNK kinases in regulating tubular salt and potassium transport and in the development of hypertension. Am J Physiol 288:F245–F252
8.
go back to reference Wade JB, Fang L, Liu J, Li D, Yang C-L, Subramanya AR, Maouyo D, Mason A, Ellison DH, Welling PA (2006) WNK1 kinase isoform switch regulates renal potassium excretion. Proc Natl Acad Sci 103:8558–8563PubMed Wade JB, Fang L, Liu J, Li D, Yang C-L, Subramanya AR, Maouyo D, Mason A, Ellison DH, Welling PA (2006) WNK1 kinase isoform switch regulates renal potassium excretion. Proc Natl Acad Sci 103:8558–8563PubMed
9.
go back to reference Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton RP (1995) Hypertension caused by truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 11:76–82PubMed Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton RP (1995) Hypertension caused by truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 11:76–82PubMed
10.
go back to reference Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW, Canessa CM, Rossier BC, Lifton RP (1994) Liddle’s syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79:407–414PubMed Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW, Canessa CM, Rossier BC, Lifton RP (1994) Liddle’s syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79:407–414PubMed
11.
go back to reference Staub O, Dho S, Henry P, Correa J, Ishikawa T, McGlade J, Rotin D (1996) WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle’s syndrome. EMBO J 15:2371–2389PubMedPubMedCentral Staub O, Dho S, Henry P, Correa J, Ishikawa T, McGlade J, Rotin D (1996) WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle’s syndrome. EMBO J 15:2371–2389PubMedPubMedCentral
12.
go back to reference Knight KK, Olson DR, Zhou R, Snyder PM (2006) Liddle’s syndrome mutations increasse Na+ transport through dual effects on epithelial Na+ surface expression and proteolytic cleavage. Proc Natl Acad Sci USA 103:2805–2808PubMed Knight KK, Olson DR, Zhou R, Snyder PM (2006) Liddle’s syndrome mutations increasse Na+ transport through dual effects on epithelial Na+ surface expression and proteolytic cleavage. Proc Natl Acad Sci USA 103:2805–2808PubMed
13.
go back to reference Disse-Nicodeme S, Desitter I, Fiquet-Kempf B, Houot AM, Stern N, Delahousse M, Potier J, Ader JL, Jeunemaitre X (2001) Genetic heterogeneity of familial hyperkalemic hypertension. J Hypertens 19:1957–1964PubMed Disse-Nicodeme S, Desitter I, Fiquet-Kempf B, Houot AM, Stern N, Delahousse M, Potier J, Ader JL, Jeunemaitre X (2001) Genetic heterogeneity of familial hyperkalemic hypertension. J Hypertens 19:1957–1964PubMed
14.
go back to reference Mansfield TA, Simon DB, Farfel Z, Bia M, Tucci JR, Lebel M, Gutkin M, Vialettes B, Christofilis MA, Kauppinen-Makelin R, Mayan H, Risch N, Lifton RP (1997) Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21. Nat Genet 16:202–205PubMed Mansfield TA, Simon DB, Farfel Z, Bia M, Tucci JR, Lebel M, Gutkin M, Vialettes B, Christofilis MA, Kauppinen-Makelin R, Mayan H, Risch N, Lifton RP (1997) Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21. Nat Genet 16:202–205PubMed
15.
go back to reference Gordon RD (1986) Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension 8:93–102PubMed Gordon RD (1986) Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension 8:93–102PubMed
16.
go back to reference Mayan H, Munter G, Shaharabany M, Mouallem M, Pauzner R, Holtzman EJ, Farfel Z (2004) Hypercalciuria in familial hyperkalemia and hypertension accompanies hyperkalemia and precedes hypertension: description of a large family with the Q565E WNK4 mutation. J Clin Endocrin Metabol 89:4025–4030 Mayan H, Munter G, Shaharabany M, Mouallem M, Pauzner R, Holtzman EJ, Farfel Z (2004) Hypercalciuria in familial hyperkalemia and hypertension accompanies hyperkalemia and precedes hypertension: description of a large family with the Q565E WNK4 mutation. J Clin Endocrin Metabol 89:4025–4030
17.
go back to reference Margolis BL, Lifschitz MD (1986) The Spitzer-Weinstein syndrome: one form of type IV renal tubular acidosis and its response to hydrochlorothiazide. Am J Kidney Dis 7:241–244PubMed Margolis BL, Lifschitz MD (1986) The Spitzer-Weinstein syndrome: one form of type IV renal tubular acidosis and its response to hydrochlorothiazide. Am J Kidney Dis 7:241–244PubMed
18.
go back to reference Spitzer A, Edelmann CM Jr, Goldberg LD, Henneman PH (1973) Short stature, hyperkalemia and acidosis: a defect in renal transport of potassium. Kidney Int 3:251–257PubMed Spitzer A, Edelmann CM Jr, Goldberg LD, Henneman PH (1973) Short stature, hyperkalemia and acidosis: a defect in renal transport of potassium. Kidney Int 3:251–257PubMed
19.
go back to reference Weinstein SF, Allan DM, Mendoza SA (1974) Hyperkalemia, acidosis, and short stature associated with a defect in renal potassium excretion. J Pediatr 85:355–358PubMed Weinstein SF, Allan DM, Mendoza SA (1974) Hyperkalemia, acidosis, and short stature associated with a defect in renal potassium excretion. J Pediatr 85:355–358PubMed
20.
go back to reference Mayan H, Vered I, Mouallem M, Tzadok-Witkon M, Pauzner R, Farfel Z (2002) Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrin Metab 87:3248–3254 Mayan H, Vered I, Mouallem M, Tzadok-Witkon M, Pauzner R, Farfel Z (2002) Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrin Metab 87:3248–3254
21.
go back to reference Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CH, Funder JW, New MI (1995) A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrin Metab 80:2263–2266 Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CH, Funder JW, New MI (1995) A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrin Metab 80:2263–2266
22.
go back to reference Morineau G, Sulmont V, Salomon R, Fiquet-Kempf B, Jeunamaitre X, Nicod J, Ferrari P (2006) Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J Am Soc Nephrol 17:3176–3184PubMed Morineau G, Sulmont V, Salomon R, Fiquet-Kempf B, Jeunamaitre X, Nicod J, Ferrari P (2006) Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J Am Soc Nephrol 17:3176–3184PubMed
23.
go back to reference Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS, Funder JW, Shackleton CH, Bradlow HL, Wei JQ, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Akkurt HI, De Santis C, New MI (1998) Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrin Metab 83:2244–2254 Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS, Funder JW, Shackleton CH, Bradlow HL, Wei JQ, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Akkurt HI, De Santis C, New MI (1998) Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrin Metab 83:2244–2254
24.
go back to reference New MI, Wilson RC (1999) Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc Natl Acad Sci USA 96:12790–12797PubMed New MI, Wilson RC (1999) Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc Natl Acad Sci USA 96:12790–12797PubMed
25.
go back to reference Li A, Tedde R, Krozowski ZS, Pala A, Li KX, Shackleton CH, Mantero F, Palermo M, Stewart PM (1998) Molecular basis for hypertension in the “type II variant” of apparent mineralocorticoid excess. Am J Hum Genet 63:370–379PubMedPubMedCentral Li A, Tedde R, Krozowski ZS, Pala A, Li KX, Shackleton CH, Mantero F, Palermo M, Stewart PM (1998) Molecular basis for hypertension in the “type II variant” of apparent mineralocorticoid excess. Am J Hum Genet 63:370–379PubMedPubMedCentral
26.
go back to reference Nunez BS, Rogerson FM, Mune T, Igarashi Y, Nakagawa Y, Phillipov G, Moudgil A, Travis LB, Palermo M, Shackleton C, White PC (1999) Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension 34:638–642PubMed Nunez BS, Rogerson FM, Mune T, Igarashi Y, Nakagawa Y, Phillipov G, Moudgil A, Travis LB, Palermo M, Shackleton C, White PC (1999) Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension 34:638–642PubMed
27.
go back to reference Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP (2000) Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:119–123PubMed Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP (2000) Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:119–123PubMed
28.
go back to reference Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM (1992) A chimaeric 11-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262–265PubMed Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM (1992) A chimaeric 11-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262–265PubMed
29.
go back to reference Lifton RP, Dluhy RG, Powers M, Rich GM, Gutkin M, Fallo, F, Gill JR, Feld L, Ganguly A, Laidlaw JC, Murnaghan DJ, Kaufman C, Stockigt JR, Ulick S, Lalouel J-M (1992) Hereditary hypertension caused by chimaeric gene duplication and ectopic expression of aldosterone synthase. Nature Genet 2:66–74PubMed Lifton RP, Dluhy RG, Powers M, Rich GM, Gutkin M, Fallo, F, Gill JR, Feld L, Ganguly A, Laidlaw JC, Murnaghan DJ, Kaufman C, Stockigt JR, Ulick S, Lalouel J-M (1992) Hereditary hypertension caused by chimaeric gene duplication and ectopic expression of aldosterone synthase. Nature Genet 2:66–74PubMed
30.
go back to reference Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC (1992) Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 89:8327–8331PubMed Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC (1992) Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 89:8327–8331PubMed
31.
go back to reference Dluhy RG, Lifton RP (1995) Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 60:48–51PubMed Dluhy RG, Lifton RP (1995) Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 60:48–51PubMed
32.
go back to reference Dluhy RG, Anderson B, Harlin B, Ingelfinger J, Lifton F (2001) Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 138:715–720PubMed Dluhy RG, Anderson B, Harlin B, Ingelfinger J, Lifton F (2001) Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 138:715–720PubMed
33.
go back to reference Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG (1998) Intracranial aneurysms and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31:445–450PubMed Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG (1998) Intracranial aneurysms and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31:445–450PubMed
34.
go back to reference Mulatero P, Morra di Cella S, Williams TA, Milan A, Mengozzi G, Chiandussi L, Gomez-Sanchez CE, Veglio F (2002) Glucocorticoid-remediable aldosteronism: low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrin Metab 87:3187–3191 Mulatero P, Morra di Cella S, Williams TA, Milan A, Mengozzi G, Chiandussi L, Gomez-Sanchez CE, Veglio F (2002) Glucocorticoid-remediable aldosteronism: low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrin Metab 87:3187–3191
35.
go back to reference Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD (2000) Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 85:3313–3318PubMed Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD (2000) Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 85:3313–3318PubMed
36.
go back to reference Gates LJ, Benjamin N, Haites NE, MacConnachie AA, McLay JS (2001) Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens 15:173–176PubMed Gates LJ, Benjamin N, Haites NE, MacConnachie AA, McLay JS (2001) Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens 15:173–176PubMed
37.
go back to reference Lafferty AR, Torpy DJ, Stowasser M, Taymana SE, Lin JP, Huggart P, Gordon RD, Stratakis CA (2000) A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 37:831–835PubMedPubMedCentral Lafferty AR, Torpy DJ, Stowasser M, Taymana SE, Lin JP, Huggart P, Gordon RD, Stratakis CA (2000) A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 37:831–835PubMedPubMedCentral
38.
go back to reference Stowasser M, Gordon RD (2004) Primary aldosteronism - careful investigation is essential and rewarding. Mol Cell Endocrinol 217:33–39PubMed Stowasser M, Gordon RD (2004) Primary aldosteronism - careful investigation is essential and rewarding. Mol Cell Endocrinol 217:33–39PubMed
39.
go back to reference Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, Chrousos GP, Stratakis CA (1998) Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 83:3214–3218PubMed Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, Chrousos GP, Stratakis CA (1998) Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 83:3214–3218PubMed
40.
go back to reference Hurley DM, Accili D, Stratakis CA, Karl M, Vamvakopoulos N, Rorer E, Constantine K, Taylor SI, Chrousos GP (1991) Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 87:680–686PubMedPubMedCentral Hurley DM, Accili D, Stratakis CA, Karl M, Vamvakopoulos N, Rorer E, Constantine K, Taylor SI, Chrousos GP (1991) Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 87:680–686PubMedPubMedCentral
41.
go back to reference Charmandari E, Kino T, Souvatzoglou E, Vottero A, Bhattacharyya N, Chrousos GP (2004) Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, genetic transmission, and clinical phenotype. J Clin Endocrinol Metab 89:1939–1949PubMed Charmandari E, Kino T, Souvatzoglou E, Vottero A, Bhattacharyya N, Chrousos GP (2004) Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, genetic transmission, and clinical phenotype. J Clin Endocrinol Metab 89:1939–1949PubMed
Metadata
Title
Heritable forms of hypertension
Author
V. Matti Vehaskari
Publication date
01-10-2009
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 10/2009
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-007-0537-8

Other articles of this Issue 10/2009

Pediatric Nephrology 10/2009 Go to the issue